


CLAIMS

1. A compound represented by formula (I):



5 or a pharmaceutically acceptable salt thereof, wherein:


X₁ represents an oxygen atom, nitrogen atom or CR²;

X₂ represents a nitrogen atom or a carbon atom;

X₃ represents a nitrogen atom or a carbon atom;

X₄ represents a nitrogen atom or a carbon atom;

10 R¹ represents the following formula (II-1):



wherein:

—X₅— represents —S— or —A₄=A₃—, A₁ is a carbon atom or a nitrogen atom, as for A₂ to A₄,

either all of A₂ to A₄ are CR⁴ or any one or two of A₂ to A₄ are nitrogen atoms and the
15 remaining two or one of A₂ to A₄ are CR⁴;

----- shows a double bond when A₁ is a carbon atom, and a single bond when A₁ is a
nitrogen atom;

R⁴ represents a hydrogen atom, lower alkyl group, lower alkyloxy group, halogen atom,
mono- or di- lower alkylamino atom, hydroxy group, lower alkyloxycarbonyl group,
20 carbamoyl group or mono- or di- lower alkylcarbamoylamino group;

A ring is the following (1) or (2), that may have 1 to 3 substituted groups selected from the
group comprising substituted group α;

(1) saturated, partially saturated, or unsaturated 5- or 6-membered ring and the ring may be
substituted by 1 or 2 oxo groups, wherein all of the constituting atoms of A ring are carbon
atoms, or
25

(2) saturated, partially saturated or unsaturated 5- or 6-membered ring that may have 1 to 3
hetero atoms selected from the group comprising N, S and O, besides carbon atoms, as for
constituting atoms of A ring and the ring may be substituted by 1 or 2 oxo groups;

R² represents a group selected from the group consisting of hydrogen atom, lower alkyl group,
30 cyano group, lower alkyloxy group, lower alkyloxycarbonyl group and trialkylsilyl group;

R³ is the following group (A) or (B) that may have 1 to 3 substituted groups selected from the group comprising halogen atom, lower alkyl group, cyano group, nitro group, lower alkyloxy group, hydroxy group and amino group;

said lower alkyl group may be substituted by a halogen atom;

group (A) a phenyl group;

group (B) an unsaturated or partially saturated 5- to 6- membered hetero ring group having 1 to 3 hetero atoms selected from the group comprising N, S and O in the ring;


with the proviso that the formula (I) excludes

4-[5-(2-naphthalenyl)-1H-[1,2,4]triazole-3-yl]-pyridine, 3-(1-3-benzodioxol-5-yl)-5-(2-ethylphenyl)-1H-1,2,4-triazole, 6-[5-(4-pyridyl)-1H-1,2,4-triazole-4-yl]-quinoline, 3-(5-phenyl-4H-[1,2,4]triazole-3-yl)naphthalene-2-ol, 3-[5-pyridine-4-yl-1H-[1,2,4]triazole-3-yl]-naphthalene-2-ol, 5-(quinoline-2-yl)-2-(3-cyano-phenyl)-tetrazole, 3-[5-(3,5-dichloropyridine-4-yl)-2-methyl-2H-[1,2,4]triazole-3-yl]-quinoline, 3-naphthalene-2-yl-5-phenyl-4H-[1,2,4]triazole, 3-benzo[1,3]dioxol-5-yl-1-methyl-5-o-tolyl-1H-[1,2,4]triazole, 5-(5-phenyl-4H-[1,2,4]triazole-3-yl)isobenzofuran-1,3-dione.


Substituted group α lower alkyl group (the lower alkyl group may be substituted by a hydroxyl group, halogen atom, aryl group di-lower alkylamino group (two di-lower alkyl groups may bound each other and form a 5- to 7- membered aliphatic hetero ring together with nitrogen atom, or 1 of the carbon atom constituting the aliphatic hetero ring may be substituted by an oxygen atom), lower alkoxy group, oxo group, lower alkyloxycarbonyl group, alkanoyloxy group or lower alkylsulfonylamino group; or when the lower alkyl group is a branched-lower alkyl group, the branched alkyls group may bound each other to form a cycloalkyl group or a cycloalkylene group with 3 to 6 carbon atoms, when the lower alkyl group is a branched-lower alkyl group, the branched alkyl groups may be bound each other to form a cycloalkyl group (the cycloalkyl group may be substituted by a lower alkyl group, hydroxy group, aralkyl group, or lower alkoxy group), when the same carbon atom constituting A ring has 2 lower alkyl groups, the lower alkyl group may form together a cycloalkyl group), cycloalkyl group (any 1 of carbon atoms constituting the cycloalkyl group may be substituted by an oxygen atom), lower alkyloxy group, halogen atom, mono- or di-lower alkylamino group, alkanoyl group, alkylsulfonyl group, lower alkyloxycarbonyl group, carbamoyl group, mono- or di-lower alkylcarbamoyl group, mono- or di-lower alkylcarbamoylamino group, amino group and hydroxyl group.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

formula (I) is formula (I-1),




formula (I-2),




(I-2)

formula (I-3),



(I-3)


or formula (I-4)



(I-4)

wherein each symbol is the same as above.


3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:
R¹ is formula (II-A):



(II-A)

wherein each symbol is the same as above.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:
formula (II-A) formula (II-B)




(II-B)


n formula (II-A) is a phenyl group.

5. The compound according to claim 3 or 4, or a pharmaceutically acceptable salt thereof, wherein:
A ring has at least 1 nitrogen atom as a constituting atom of the A ring.

6. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:
formula (II-A) is a group represented by formula (II-C)



or (II-D)



wherein X^6 represents CH_2 , $CH=CH$ or $CH-CH$, and as for X_7 to X_{10} , 1 of X_7 to X_{10} is a
 5 nitrogen atom, and the rest are carbon atoms;

said group may have 1 to 3 substituted groups selected from the above mentioned substituted
 group α that ring A may have.

7. The compound according to claim 6, wherein formula (II-A) is formula (II-C), or a pharmaceutically
 10 acceptable salt thereof.
8. The compound according to claim 6, wherein formula (II-A) is formula (II-D), or a pharmaceutically
 acceptable salt thereof.
- 15 9. The compound according to any one of claims 1, 2, 3 or 4, or a pharmaceutically acceptable salt
 thereof, wherein:
 formula (I) is formula (I-1) or formula (I-4) ;
 with the proviso that R^1 is a substituted or non-substituted naphthyl group.
- 20 10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by the formula (I) is:
 5-methyl-1-phenyl-4-(quinoline-6-yl)-1H-[1,2,3]triazole,
 5-methyl-4-(1-oxo-indene-5-yl)-1-phenyl-1H-[1,2,3]triazole,
 5-methyl-4-(2-methylbenzothiazole-5-yl)-1-phenyl-1H-[1,2,3]triazole,
 25 4-(1H-indole-5-yl)-5-methyl-1-phenyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(quinoline-6-yl)-1H-[1,2,3]triazole,
 5-methyl-4-(naphthalene-2-yl)-5-methyl-1H-[1,2,3]triazole,
 4-(3-cyclohexyl-5-fluoro-6-methyl-4-oxo-4H-chromen-7-yl)-5-methyl-1-phenyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-methyl-quinoline-6-yl)-1H-[1,2,3]triazole,
 30 1-(2-fluoropyridine-3-yl)-5-methyl-4-quinoxaline-6-yl)-1H-[1,2,3]triazole,
 4-(1,3-dioxo-2,3-dihydro-1H-isoindole-5-yl)-5-methyl-1-phenyl-1H-[1,2,3]triazole,

- 4-(1,3-dioxo-2,3-dihydro-2-methyl-1H-isoindole-5-yl)-5-methyl-1-phenyl-1H-[1,2,3]triazole,
 4-(2,2-dimethyl-1-oxo-indene-5-yl)-5-methyl-1-phenyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-methyl-imidazo[1,2-a]pyridine-6-yl)-1H-[1,2,3]triazole,
 5-methyl-4-(4-oxo-4H-chromen-6-yl)-1-phenyl-1H-[1,2,3]triazole,
 5 1-(2-fluoropyridine-3-yl)-5-methyl-4-([1,2,4]triazolo[4,3-a]pyridine-7-yl)-1H-[1,2,3]triazole,
 4-(3,4-dihydro-2H-1-oxa-9-aza-anthracene-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-([1,2,4]triazolo[4,3-a]pyridine-6-yl)-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-4-isoquinoline-7-yl-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-4-isoquinoline-3-yl-5-methyl-1H-[1,2,3]triazole,
 10 1-(2-fluoropyridine-3-yl)-4-(2,2-dimethyl-1-oxo-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-5-yl)-5-methyl-4-(2-methyl-quinoline-6-yl)-1H-[1,2,3]triazole,
 1-(6-chloro-[1,5]naphthyridine-2-yl)-4-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(5,6,7,8-tetrahydro-[1,5]naphthyridine-2-yl)-1H-[1,2,3]triazole,
 15 4-(5-acetyl-5,6,7,8-tetrahydro-[1,5]naphthyridine-2-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 4-(2-chloroquinoline-6-yl)-1-(2-fluoropyridine-3-yl)-1-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-methyl-1-oxoindene-5-yl)-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-((2R*)-methyl-1-oxoindene-5-yl)-1H-[1,2,3]triazole,
 20 1-(2-fluoropyridine-3-yl)-5-methyl-4-((2S*)-methyl-1-oxoindene-5-yl)-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-5-yl)-4-(2,2-dimethyl-1-oxo-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-4-(4-oxo-4H-chromen-7-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-4-(2-methoxyquinoline-6-yl)-5-methyl-1H-[1,2,3]triazole,
 4-(2-tert-butyl-imidazo[1,2-a]pyridine-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 25 1-(2-fluoropyridine-3-yl)-5-methyl-4-(1-oxo-indene-2-spiro-1'-cyclobutane-5-yl)-1H-[1,2,3]triazole,
 4-(2-dimethylamino-quinoline-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(1-oxo-indene-2-spiro-1'-cyclopropyl-5-yl)-1H-[1,2,3]triazole,
 4-(2-chloro-3-ethyl-quinoline-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 30 1-(2-fluoropyridine-3-yl)-4-(2-methoxy-1-oxo-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-morpholine-4-yl-quinoline-6-yl)-1H-[1,2,3]triazole,
 4-(3-methyl-4-oxo-4H-chromen-7-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-4-(2-(4-methylpiperazine-1-yl)-quinoline-6-yl)-5-methyl-1H-[1,2,3]triazole,
 4-(2-isopropyl-imidazo[1,2-a]pyridine-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
 35 1-(2-fluoropyridine-3-yl)-4-(5-oxo-5,6,7,8-tetrahydro-naphthalene-2-yl)-5-methyl-1H-[1,2,3]triazole,
 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-methyl-1-oxo-isoindoline-5-yl)-1H-[1,2,3]triazole,
 4-(2-ethyl-3-methyl-imidazo[1,2-a]pyridine-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-

- [1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(1-oxo-2-methylcarbonyloxy-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-5-yl)-4-(2-isopropyl-imidazo[1,2-a]pyridine-6-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(1-oxo-4-hydroxy-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 5 4-(2-cyclopropyl-imidazo[1,2-a]pyridine-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-cyclopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-isopropyl-1-oxo-indene-5-yl)—1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(2-methyl-2-methylcarbonyloxy-1-oxo-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 10 1-(2-fluoropyridine-3-yl)-4-(2-hydroxy-2-methyl-1-oxo-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(2-methoxy-2-methyl-1-oxo-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-((2S*)-methoxy-(2R*)-methyl-1-oxoindene-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-((2R*)-methoxy-(2S*)-methyl-1-oxoindene-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 15 1-(2-fluoropyridine-3-yl)-4-(2-pyrrolidine-1-yl-quinoline-6-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-methyl-4-oxo-4-methyl-chromen-7-yl)-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-5-yl)-4-(1-oxo-2-methyl-indene-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-5-methyl-4-(1-oxo-1H-indene-5-yl)-1H-[1,2,3]triazole,
- 20 1-(2-fluoropyridine-3-yl)-4-(2-methyl-1-oxo-1H-inden-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-5-yl)-4-(3-methyl-4-oxo-4H-chromen-7-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-cyclopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(benzothiazole-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(5-fluoro-3-methyl-4-oxo-4H-chromen-7-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 25 5-methyl-4-(3-methyl-4-oxo-4H-chromen-7-yl)-1-(pyridine-3-yl)-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(2-methanesulfonyl-quinoline-6-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-[(2-isopropyl-methyl-amino)-quinoline-6-yl]-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(3-benzyl-4-oxo-3,4-dihydroquinazoline-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(5-oxo-6-methyl-5,6,7,8-tetrahydro-naphthalene-2-yl)-5-methyl-1H-[1,2,3]triazole,
- 30 4-(3-benzyl-4-oxo-3,4-dihydroquinazoline-6-yl)-1-phenyl-1H-[1,2,3]triazole,
- 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-4-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-tert-butyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-ethyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 35 1-(2-fluoropyridine-3-yl)-4-(2-methoxy-4-oxo-4H-chromen-7-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(3-methyl-4-oxo-3,4-dihydro-quinazoline-7-yl)-5-methyl-1H-[1,2,3]triazole,

- 1-(2-fluoropyridine-3-yl)-4-(3-methyl-4-oxo-3,4-dihydro-quinazoline-6-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-[2-(2-hydroxy-1-methyl-ethyl)-1-oxo-isoindoline-5-yl]-5-methyl-1H-[1,2,3]triazole,
- 5 1-(2-fluoropyridine-3-yl)-5-methyl-(2,3-dimethyl-4-oxo-3,4-dihydro-quinazoline-7-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(3-methyl-4-oxo-chroman-7-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-((3R*)-methyl-4-oxo-chroman-7-yl)-5-methyl-1H-[1,2,3]triazole,
- 10 1-(2-fluoropyridine-3-yl)-4-((3S*)-methyl-4-oxo-chroman-7-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-4-(1-oxo-isoindoline-5-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(3-benzyl-4-oxo-3,4-dihydroquinazoline-7-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-5-yl)-4-(2-isopropyl-imidazo[1,2-a]pyridine-6-yl)-5-methyl-1H-[1,2,3]triazole,
- 15 4-(3-benzyl-2-ethyl-4-oxo-3,4,-dihydroquinazoline-7-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-propyl-1-oxo-isoindoline-5-yl)-1H-[1,2,3]triazole,
- 4-(2-benzyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-cyclopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 20 4-(2-cyclopropylmethyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-isobutyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-5-methyl-4-(3-methyl-4-oxo-4H-pyrano[2,3-b]pyridine-7-yl)-1H-[1,2,3]triazole,
- 25 4-(3,3-dimethyl-4-oxo-chroman-7-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-cyclopropyl-1-oxo-isoindoline-5-yl)-1-phenyl-5-methyl-1H-[1,2,3]triazole,
- 1-(2-fluoropyridine-3-yl)-5-methyl-4-(1a-methyl-2-oxo-1,1a,2,7a-tetrahydro-7-oxo-6-cyclopropa[b]naphthalene-5-yl)-1H-[1,2,3]triazole,
- 4-(2-methyl-1-oxo-isoquinoline-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 30 4-(2-ethyl-imidazo[1,2-a]pyridine-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-methyl-1-oxo-3,4-dihydroisoquinoline-6-yl)-1-(2-fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole,
- 4-([1,8]naphthyridine-3-yl)-4-phenyl-5-methyl-1H-[1,2,3]triazole,
- 5-(2-cyclopropyl-1-oxo-isoindoline-5-yl)-1-(2-fluoropyridine-3-yl)-4-carbonitril-1H-[1,2,3]triazole,
- 35 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2,4-difluorophenyl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-(2,2-difluoroethyl)-1-oxo-isoindoline-5-yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole,
- 4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoindoline-5-yl)-1-(4-fluorophenyl)-5-methyl-1H-

[1,2,3]triazole,
 4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl)-1-(4-fluorophenyl)-5-methyl-1H-
 [1,2,3]triazole, or
 1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole.

5

11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by formula (I) is 1-(2-fluoropyridine-3-yl)-5-methyl-4-(1-oxoindene-2-
 spiro-1'-cyclopropyl-5-yl)-1H-[1,2,3]triazole.

10 12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by formula (I) is 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2-
 fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole.

13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 15 the compound represented by formula (I) is 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2-
 fluoropyridine-3-yl)-5-methyl-1H-[1,2,3]triazole.

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by formula (I) is 1-(2-fluoropyridine-3-yl)-5-methyl-4-(2-propyl-1-oxo-
 20 isoindoline-5-yl)-1H-[1,2,3]triazole.

15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by formula (I) is 4-(2-cyclopropyl-1-oxo-isoindoline-5-yl)-1-(2-
 fluorobenzene-3-yl)-5-methyl-1H-[1,2,3]triazole.

25

16. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by formula (I) is 4-(2-isopropyl-1-oxo-isoindoline-5-yl)-1-(2,4-
 difluorophenyl)-5-methyl-1H-[1,2,3]triazole.

30 17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 the compound represented by formula (I) is 4-(2-(2,2-difluoroethyl)-1-oxo-isoindoline-5-yl)-1-(4-
 fluorophenyl)-5-methyl-1H-[1,2,3]triazole.

18. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 35 the compound represented by formula (I) is 4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoindoline-5-
 yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole.

19. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
the compound represented by formula (I) is 4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole, or a pharmaceutically acceptable salt thereof.
- 5 20. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
the compound represented by formula (I) is 1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole.
- 10 21. An mGluR1 inhibitor having any one of the compound according to claims 1 to 10 or pharmaceutical salts thereof as active ingredients.
- 15 22. A treating and/or preventing agent of convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease or gastrointestinal disorder, having any one of the compound according to claims 1 to 10 or pharmaceutical salts thereof as active ingredients.